期刊文献+

影响胰头癌根治术预后的多因素分析——肿瘤出芽是预后的独立影响因素 被引量:5

Multivariate Analysis of Predictors of Pancreatic Head Cancer after Total Resection:Tumor Budding is an Independent Factor
暂未订购
导出
摘要 目的探讨肿瘤出芽在胰头癌根治术后评价预后中的作用。方法肿瘤出芽定义为肿瘤浸润前沿的单个或一簇个数<5的肿瘤细胞,200倍显微镜视野下(0.785 mm2)计数肿瘤出芽的个数。回顾性分析2005~2010年67例因胰头癌行根治性切除术患者的临床病理资料及随访资料,对影响预后的临床病理因素进行多因素分析。结果 (1)67例胰头癌患者中肿瘤出芽个数0~59个/0.785 mm2,中位数19个/0.785 mm2。采用接受者运行曲线(ROC)定义肿瘤出芽个数≥17为肿瘤出芽高密度组,<17为肿瘤出芽低密度组。本研究肿瘤出芽高密度组39例(58.2%),低密度组28例(41.8%)。肿瘤出芽高密度组年龄小(P=0.007),T分期高(P=0.007),N分期高(P=0.002),AJCC分期高(P=0.004),神经浸润发生率高(P=0.004),组织学分级高(P=0.001),术后早期复发多(P=0.001),2年生存率低(P=0.000)。(2)存活26例,死亡41例。中位生存时间12个月(3~59个月)。单因素分析结果显示,T分期(P=0.009)、N分期(P=0.003)、AJCC分期(P=0.006)、组织学分级(P=0.034)和肿瘤出芽(P=0.000)与胰头癌患者的生存时间有关,多因素Cox回归分析结果显示,肿瘤出芽高密度是胰头癌患者预后的独立影响因素(HR=3.093,95%CI 1.314~7.283,P=0.010)。结论肿瘤出芽高密度是胰头癌根治性切除术后预后不良的重要因素。 Objective To investigate the role of tumor budding in predicting the prognosis of pancreatic cancer after total resection. Methods Tumor budding was defined as a single or a cluster of tumor cells ( 〈 5 tumor cells) infiltrating the stroma at the invasive front, the number of tumor budding was counted in a × 200 microscopic field (0. 785 mm^2 ). The clinical, pathological and follow-up data of 67 patients with pancreatic head cancer, who received total resection in our hospital from 2005 to 2010, were enrolled into this study for a multivariate analysis of the predictors 59/0. 785 mm2 , with a median of 19/0. 785 mm^2 in the 67 cases. of the tumor. Results The number of tumor budding was 0 - Based on receiver operation curve (ROC) , the number of tumor budding ≥17 was defined as high-density group (39 cases, 58.2% ) , and 〈 17 was low-density group (28 cases, 41.8% ). High- density group showed significantly younger age ( P = 0. 007 ) , higher T classification ( P = 0. 007 ), higher N stage ( P = 0. 002 ) , higher AJCC staging (P = 0. 004), higher incidence of perineural invasion ( P = 0. 004), higher G grade ( P = 0. 001 ), more early recurrence (P = 0. 001 ), and lower 2-year survival rate ( P = 0. 000) than the low-density group. Totally 26 patients survived, the other 41 died. The median survival time was 12 months (3 to 59 months). Univariate analysis showed that T classification (P = 0. 009) , N stage ( P = 0. 003 ), AJCC staging ( P = 0. 006) , G grade (P = 0. 034), and tumor budding ( P = 0. 000) were related to the survival time of patients with pancreatic head cancer. And Cox regression confirmed that tumor budding was the only independent prognostic factor of pancreatic head cancer ( HR = 3. 093, 95% CI 1. 314 - 7. 283, P = 0. 010). Conclusions High-density tumor budding is an important negative prognostic factor for pancreatic head cancer.
出处 《中国微创外科杂志》 CSCD 2012年第7期604-607,共4页 Chinese Journal of Minimally Invasive Surgery
关键词 胰腺癌 肿瘤出芽 肿瘤复发 预后 Pancreatic cancer Tumor budding Recurrence Prognosis
  • 相关文献

参考文献8

  • 1Bruno M, Hans MA. Prognoslic significance of tumor budding in gastroiuteslinal tumors. Expert Rev Anticancer Ther, 2011 , 11 ( 10 ) :1521 - 1533.
  • 2Prall F. Tumour budding in colorectal carcinoma. Histopathology, 2007,50( 1 ) :151 - 162.
  • 3黄文斌,赵建华,周晓军.结直肠癌中肿瘤出芽现象的研究[J].诊断病理学杂志,2008,15(6):493-496. 被引量:4
  • 4Ueno H,Murphy J,Jass JR,et al. Tumor "budding" as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology ,2002,40 ( 2 ) : 127 - 132.
  • 5Kalluri R, Weinberg RA. The basics of epithelial - mesenchymal transition. J Clin Invest ,2009,119 ( 6 ) : 1420 - 1428.
  • 6Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathohogy. Pathology. 2007,39 ( 3 ) : 305 - 318.
  • 7Zlnbec l. Lugli A. Epithelial mesenchymal transition anti tumor buddirlg in aggressive colorectal t'ant'er:lamor budding as oncolargel. Oncotarget,2010,1 (7) :651 -661.
  • 8Thiery JP, Acloque H. Huang RY, el al. F, pithelial-mesenchymal transitions in development and disease. Cell. 2009, 139 ( 5 ) : 871 -890.

二级参考文献1

共引文献3

同被引文献43

  • 1蒋慧,边云,郑建明.病理大切片结合人工智能在胰腺肿瘤诊疗中的应用前景[J].中华胰腺病杂志,2019,19(5):347-351. 被引量:6
  • 2Renyi Qin,Michael L.Kendrick,Christopher L.Wolfgang,Barish H.Edil,Chinnusamy Palanivelu,Rowan WParks,Yinmo Yang,Jin He,Taiping Zhang,Yiping Mou,Xianjun Yu,Bing Peng,Palanisamy Senthilnathan,Ho-Seong Han,Jae Hoon Lee,Michiaki Unno,Steven WMOlde Damink,Virinder Kumar Bansal,Pierce Chow,Tan To Cheung,Nim Choi,Yu-Wen Tien,Chengfeng Wang,Manson Fok,Xiujun Cai,Shengquan Zou,Shuyou Peng,Yupei Zhao.International expert consensus on laparoscopic pancreaticoduodenectomy[J].Hepatobiliary Surgery and Nutrition,2020,9(4):464-483. 被引量:64
  • 3鲍云华,李俭杰.介绍新的实体瘤治疗反应评价标准(RECIST)[J].中国肺癌杂志,2005,8(1):77-78. 被引量:116
  • 4Barkin JS,Goldstein JA.Diagnostic and therapeutic approach to pancreatic cancer[J].Biomed Pharmacother,2000,54(7):400-409.
  • 5Vincent A,Herman J,Schulick R,et al.Pancreatic cancer[J].Lancet,2011,378(9791):607-620.
  • 6Haller DG.New perspectives in the management of pancreas cancer[J].Semin Oncol,2003,30(4 Suppl 11):3-10.
  • 7Okada Y,Takeyama H,Sato M,et al.Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing cret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF)[J].Int J Cancer,1999,81 (1):67-73.
  • 8Zhongmin W,Yu L,Fenju L,et al.Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer[J].Eur Radiol,2010,20(7):1786-1791.
  • 9Zhang FJ,Wu PH,Zhao M,et al.CT guided radioactive seed 125I implantation in treatment of pancreatic cancer[J].Zhonghua Yi Xue Za Zhi,2006,86(4):223-227.
  • 10郭道宁,王鸿智,王东,漆家高,杨培,罗华,匡铭.超声导向下经皮穿刺^(125)I粒子植入治疗胰腺癌的临床运用[J].中国超声医学杂志,2008,24(1):53-55. 被引量:11

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部